Orchard Therapeutics PLC (ORTX) Stock
ORTX is no longer traded. Orchard Therapeutics was delisted from the Nasdaq in January 2024.
Prices on this page are historical; the last trade was January 23, 2024 at $16.70.
Orchard Therapeutics stock price history
ORTX final trading statistics
- Final close
- $16.70
- Final trading day
- Jan 23, 2024
- Market cap at delisting
- $380.11M
- Shares outstanding
- 22.76M
- Final 52-week range
- $0.45 – $16.72
- Avg. volume (final 3 mo.)
- 108,280
- All-time high (split-adj.)
- $206.30 · Apr 2019
- All-time low (split-adj.)
- $3.65 · Dec 2022
- Return since IPO
- -88.1%
- Beta
- 0.55
- Book value / share
- $3.53
- Price / book
- 4.73
Orchard Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $21.84M | -$72.9M | — |
| FY2022 | $6.99M | -$7.9M | -$11.50 |
| FY2021 | $483.0K | -$36.3M | -$11.80 |
| FY2020 | $2.60M | -$152.0M | -$15.30 |
| FY2019 | $2.51M | -$163.4M | -$17.50 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Orchard Therapeutics PLC
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..
Orchard Therapeutics stock FAQ
What happened to Orchard Therapeutics stock?
Orchard Therapeutics stock was delisted from the Nasdaq. Its final close was $16.70 on January 23, 2024.
Is ORTX stock still trading?
No. ORTX was delisted from the Nasdaq in January 2024 and no longer trades on a U.S. exchange.
What was the last price of ORTX stock?
ORTX closed at $16.70 on its final trading day, January 23, 2024, for a market value of about $380.11M.
What were Orchard Therapeutics's revenue and earnings in its last full fiscal year?
Orchard Therapeutics reported revenue of $21.84M and net income of -$72.9M in fiscal 2023, its last full year as a public company.
When did Orchard Therapeutics go public?
Orchard Therapeutics PLC stock began trading on October 31, 2018.